Skip to content

Impact of Web Application Support Versus Standard Management on Compliance With Adjuvant Hormone Therapy at 18 Months in Patients Treated for Breast Cancer

Impact of Web Application Support Versus Standard Management on Compliance With Adjuvant Hormone Therapy at 18 Months in Patients Treated for Breast Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04554927
Acronym
WEBAPPAC
Enrollment
438
Registered
2020-09-18
Start date
2020-09-03
Completion date
2026-12-31
Last updated
2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Hormono Therapy, Web-application

Brief summary

The investigators hypothesize that the implementation of a Web-application in patients initiating adjuvant hormone therapy for breast cancer brings a benefit on treatment adherence and quality of life.

Interventions

The patients of the Web-application arm will be trained on the devices and the application will be installed either on their smartphone or on another support (computer, tablet).

OTHERStandard accompaniment

Personalized schedule of medical follow-up given to the patient

Sponsors

Centre Francois Baclesse
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient \> 18 years old * Breast cancer patient candidate for adjuvant hormone therapy * Mastery of the French language * Patient with a cell phone and an Internet connection * Patient able to use a computer, smartphone, or tablet. * Patient affiliated to a social security system * Signing of informed consent prior to any specific study-related procedure

Exclusion criteria

* Patient who has previously received hormone therapy for cancer. * Patient not trained in the use of the application * Any associated medical or psychiatric condition that might compromise the patient's ability to participate in the study * Patients with locoregional or metastatic recurrence * Other history of cancer. * Patient deprived of liberty, under guardianship or curatorship * Simultaneous participation in a therapeutic clinical trial or other clinical study involving a connected tool * Patient unable to undergo trial follow-up for geographical, social or psychopathological reasons

Design outcomes

Primary

MeasureTime frameDescription
Observance of hormontherapy18 monthsEvaluate the benefit of a web-based application on hormone therapy compliance (Morisky questionnary; answer Yes or No; 8 questions)

Secondary

MeasureTime frameDescription
Quality of life with self questionnaires18 monthsQuality of life scores according (EORTC QLQ-C30 self-questionnaires ; minimum not at all to maximum Lot; 30 questions)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 19, 2026